These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23621771)

  • 1. 5-Azacytidine for the treatment of myelodysplastic syndromes.
    Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
    Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Azacytidine/Azacitidine.
    Müller A; Florek M
    Recent Results Cancer Res; 2010; 184():159-70. PubMed ID: 20072837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
    Santini V
    Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of hypomethylating agents in myelodysplastic syndromes.
    Atallah E; Garcia-Manero G
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.
    Douvali E; Papoutselis M; Vassilakopoulos TP; Papadopoulos V; Spanoudakis E; Tsatalas C; Kotsianidis I
    Leuk Res; 2013 Aug; 37(8):889-93. PubMed ID: 23726719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine for the treatment of myelodysplastic syndrome.
    Cataldo VD; Cortes J; Quintás-Cardama A
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine.
    Gore SD; Jones C; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522
    [No Abstract]   [Full Text] [Related]  

  • 18. Azacitidine.
    Issa JP; Kantarjian HM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
    [No Abstract]   [Full Text] [Related]  

  • 19. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
    Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
    Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
    Fenaux P; Ades L
    Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.